Close Menu

NEW YORK – A triple-pronged therapy that simultaneously targets BRAF, EGFR, and MEK seems to stretch out overall survival times in BRAF-mutated metastatic colorectal cancer cases, according to results from a randomized Phase III clinical trial called BEACON.

"We're hopeful that this will give new options for our [BRAF-mutated metastatic CRC] patients," said Scott Kopetz, a gastrointestinal medical oncologist at the University of Texas MD Anderson Cancer Center, principal investigator on BEACON and co-lead for MD Anderson's Cancer Moon Shot effort in CRC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.


This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.